Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Added Small cell lung carcinoma as a condition tag and introduced a Resources section linking Genetic and Rare Diseases Information Center.
    Difference
    0.1%
    Check dated 2026-04-02T15:35:48.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T06:19:35.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3 on the page; this reflects a backend/UI update and does not modify study data or content.
    Difference
    0.0%
    Check dated 2026-03-12T02:46:29.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page, and the funding-status notice and Revision: v3.4.1 were removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:35:58.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding affecting updates was added, and the page revision tag was updated from v3.4.0 to v3.4.1, to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:36:27.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Additions include showing glossary and revision/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); Deletions remove the previous lowercase QC label (Last Update Submitted that met QC Criteria), No FEAR Act data, and an older revision stamp (Revision: v3.3.4). These are minor metadata/label changes and do not affect core study content such as results, eligibility criteria, or key dates; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:23:35.000Z thumbnail image

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.